Revenue
287 thousand USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 287234 USD Source
Annual consolidated revenue for 2025: about USD 151.4K, using the latest reported figures. The previous period, 2024, was about USD 1.691M.
3958 USD
40666086 shares
1.93% · 771 thousand shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
16.6 thousand USD
2025-07-01 – 2026-06-30
-12.2 million USD
2025-07-01 – 2026-06-30
516 thousand USD
2025-07-01 – 2026-06-30
0 USD
2025-07-01 – 2026-06-30
516 thousand USD
2025-07-01 – 2026-06-30
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-20.
Financial data available through: 2025-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Prior period
USD 1.69 million
–
Current period
USD 151,388
–
151388 − 1691241 = -1539853 USD
1691241 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source151388 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
−USD 596,394
–
Current period
−USD 12.32 million
–
-12319516 − -596394 = -11723122 USD
-596394 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-12319516 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
−USD 155,903
–
Current period
USD 824,517
–
824517 − -155903 = 980420 USD
-155903 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source824517 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
USD 0
–
Current period
USD 0
–
0 − 0 = 0 USD
0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | 2084939 | 7246991 Derived | -5162052 | 57015 Derived | -5219067 | -2621830 Derived | Source
|
| 2021 2021-01-01 – 2021-12-31 | 2000000 | 2214598 Derived | -214598 | 281 Derived | -214879 | 819083 Derived | Source
|
| 2022 2022-01-01 – 2022-12-31 | 1966202 | 2553636 Derived | -587434 | -100276 Derived | -487158 | 522061 Derived | Source
|
| 2023 2023-01-01 – 2023-12-31 | 2000000 | 8546440 Derived | -6546440 | -288 Derived | -6546152 | -433140 Derived | Source
|
| 2024 2024-01-01 – 2024-12-31 | 1691241 | 3847975 Derived | -2156734 | -1560340 Derived | -596394 | -155903 Derived | Source
|
| 2025 2025-01-01 – 2025-12-31 | 151388 | 14074247 Derived | -13922859 | -1603343 Derived | -12319516 | 824517 Derived | Source
|
Amounts are exact, in USD.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Revenue | 2084939 |
|
| 2021 | Revenue | 2000000 |
|
| 2022 | Revenue | 1966202 |
|
| 2023 | Revenue | 2000000 |
|
| 2024 | Revenue | 1691241 |
|
| 2025 | Revenue | 151388 |
|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Year over year | No prior comparable period |
|
| 2021 | Year over year | No prior comparable period |
|
| 2022 | Year over year | -1.7% |
|
| 2023 | Year over year | 1.7% |
|
| 2024 | Year over year | -15.4% |
|
| 2025 | Year over year | -91% |
|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Operating margin | -247.6% |
|
| 2021 | Operating margin | -10.7% |
|
| 2022 | Operating margin | -29.9% |
|
| 2023 | Operating margin | -327.3% |
|
| 2024 | Operating margin | -127.5% |
|
| 2025 | Operating margin | -9,196.8% |
|
| 2015 | Net margin | -250.3% |
|
| 2021 | Net margin | -10.7% |
|
| 2022 | Net margin | -24.8% |
|
| 2023 | Net margin | -327.3% |
|
| 2024 | Net margin | -35.3% |
|
| 2025 | Net margin | -8,137.7% |
|
| 2015 | Free cash flow margin | -125.8% |
|
| 2021 | Free cash flow margin | 41% |
|
| 2022 | Free cash flow margin | 26.6% |
|
| 2023 | Free cash flow margin | -21.7% |
|
| 2024 | Free cash flow margin | -9.2% |
|
| 2025 | Free cash flow margin | 544.6% |
|
Cash generated by the company’s normal business operations.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Operating cash flow | -2434789 |
|
| 2021 | Operating cash flow | 819083 |
|
| 2022 | Operating cash flow | 522061 |
|
| 2023 | Operating cash flow | -433140 |
|
| 2024 | Operating cash flow | -155903 |
|
| 2025 | Operating cash flow | 824517 |
|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Free cash flow | -2621830 |
|
| 2021 | Free cash flow | 819083 |
|
| 2022 | Free cash flow | 522061 |
|
| 2023 | Free cash flow | -433140 |
|
| 2024 | Free cash flow | -155903 |
|
| 2025 | Free cash flow | 824517 |
|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Liabilities / assets | 143.7% |
|
| 2021 | Liabilities / assets | 1.3% |
|
| 2022 | Liabilities / assets | 13.9% |
|
| 2023 | Liabilities / assets | 8.2% |
|
| 2024 | Liabilities / assets | 8.8% |
|
| 2025 | Liabilities / assets | 8% |
|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Current assets / current liabilities | 0.51× |
|
| 2021 | Current assets / current liabilities | 1.87× |
|
| 2022 | Current assets / current liabilities | 3.14× |
|
| 2023 | Current assets / current liabilities | 2.61× |
|
| 2024 | Current assets / current liabilities | 5.01× |
|
| 2025 | Current assets / current liabilities | 4× |
|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | −USD 5.22 million Exact valueExact value: -5219067 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.43 million Exact valueExact value: -2434789 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 187,041 Exact valueExact value: 187041 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.62 million Calculation and evidence-2434789 − 187041 USD Exact free cash flow: -2621830 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2016 2016-01-01 – 2016-12-31 | −USD 11.82 million Exact valueExact value: -11816521 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2 million Exact valueExact value: -2003860 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 4,540 Exact valueExact value: 4540 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.01 million Calculation and evidence-2003860 − 4540 USD Exact free cash flow: -2008400 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | −USD 214,879 Exact valueExact value: -214879 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 819,083 Exact valueExact value: 819083 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 819,083 Calculation and evidence819083 − 0 USD Exact free cash flow: 819083 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | −USD 487,158 Exact valueExact value: -487158 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 522,061 Exact valueExact value: 522061 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 522,061 Calculation and evidence522061 − 0 USD Exact free cash flow: 522061 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | −USD 6.55 million Exact valueExact value: -6546152 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 433,140 Exact valueExact value: -433140 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 433,140 Calculation and evidence-433140 − 0 USD Exact free cash flow: -433140 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 596,394 Exact valueExact value: -596394 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 155,903 Exact valueExact value: -155903 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 155,903 Calculation and evidence-155903 − 0 USD Exact free cash flow: -155903 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 12.32 million Exact valueExact value: -12319516 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 824,517 Exact valueExact value: 824517 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 824,517 Calculation and evidence824517 − 0 USD Exact free cash flow: 824517 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
37 filings · 1,988 latest values · 1,983 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001593549, 1593549, LIVG, NUGN, edgar:1593549
Also known as Bling Marketing, Inc., LIVENTO GROUP, INC., LIVENTO Group, Inc., Livento Group, Inc., NuGene International, Inc.